caa a22 4500 445333073 CHVBK 20180317142743.0 cr unu---uuuuu 170323e20110101xx s 000 0 eng 10.1245/s10434-010-1229-3 doi (NATIONALLICENCE)springer-10.1245/s10434-010-1229-3 Systematic Review on the Efficacy of Multimodal Treatment of Sarcomatosis with Cytoreduction and Intraperitoneal Chemotherapy [Elektronische Daten] [Gitonga Munene, Lloyd Mack, Walley Temple] Background: Peritoneal sarcomatosis carries a dismal prognosis with median survival of 12months and no 5-year survivors. The treatment for sarcomatosis has mostly been chemotherapy and surgery for palliation. Recently, cytoreduction (CRS) and intraperitoneal chemotherapy (IPC) has been tried as an alternative for improving regional control and survival, but the efficacy of this combined treatment is difficult to determine. The objective of this review is to evaluate all available evidence to determine the efficacy of this treatment modality. Materials and Methods: Searches for studies published in peer-reviewed journals before October 2010 were carried out on 3 databases. The reference lists of all identified articles were reviewed for further relevant studies. Relevant studies were then evaluated by 3 investigators, and the quality of each study was assessed. Studies that met an established criterion were reviewed for clinical effectiveness with a tabulation of all results. Results: Eight prospective and one randomized trial were available representing 240 patients treated with CRS and IPC. The median disease-free survival ranged from 2.3 to 22months, median survival ranged from 5.5 to 39.6months, and the 5-year survival ranged from 7% to 65%. The surgical morbidity varied from 9% to 44% and the mortality from 0% to 11%. Conclusions: Based on the available data, this treatment approach is currently not recommended in the treatment of sarcomatosis except in experienced centers, in well-selected patients and as part of an experimental protocol. Society of Surgical Oncology, 2010 Munene Gitonga Divisions of Surgical Oncology and General Surgery, Department of Surgery, University of Calgary and the Tom Baker Cancer Centre, Calgary, AB, Canada aut Mack Lloyd Divisions of Surgical Oncology and General Surgery, Department of Surgery, University of Calgary and the Tom Baker Cancer Centre, Calgary, AB, Canada aut Temple Walley Divisions of Surgical Oncology and General Surgery, Department of Surgery, University of Calgary and the Tom Baker Cancer Centre, Calgary, AB, Canada aut Annals of Surgical Oncology Springer-Verlag 18/1(2011-01-01), 207-213 1068-9265 18:1<207 2011 18 10434 https://doi.org/10.1245/s10434-010-1229-3 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-010-1229-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Munene Gitonga Divisions of Surgical Oncology and General Surgery, Department of Surgery, University of Calgary and the Tom Baker Cancer Centre, Calgary, AB, Canada aut NATIONALLICENCE 700 1- Mack Lloyd Divisions of Surgical Oncology and General Surgery, Department of Surgery, University of Calgary and the Tom Baker Cancer Centre, Calgary, AB, Canada aut NATIONALLICENCE 700 1- Temple Walley Divisions of Surgical Oncology and General Surgery, Department of Surgery, University of Calgary and the Tom Baker Cancer Centre, Calgary, AB, Canada aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/1(2011-01-01), 207-213 1068-9265 18:1<207 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer